Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Technology · ·
$1.26
▼ $0.02 (-1.6%)
Market data updated: 09/20 12:01 PM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$19.77M
Day Range
$1.17 - $1.32
52-Week Range
$0.62 - $3.15
Beta
—
Next Earnings
—
Support
$0.93
Resistance
$1.44
AIFF is a stock from the Technology sector — Software, hardware, chip, and computing-services companies — revenue tied to the pace of innovation and upgrade cycles.
-57.6% (1Y)
Strengths: 10/27 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 957.4%
Growth
Biggest negative driver
Operating margin
Operating margin: -775.5% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
48
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
1d ago · $1.26
Evidence: FOMO score jumped from 16 to 70 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
Not enough data yet to generate this synthesis.
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
46
Quality
42
Value
50
Momentum
70
Risk
34
Sentiment
44
Fundamental
31
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **Firefly Neuroscience, Inc.** has highlighted its expansion in **transcranial magnetic stimulation (TMS) services**, reporting a **291% surge in brain scan volumes** at its TMS centers. The company also partnered with **Next Health** to launch a **Precision Cognitive Health Initiative**, leveraging Firefly’s **FDA-cleared EEG/ERP brain biomarker technology** alongside **personalized cognitive peptide protocols**, following an **FDA Advisory Committee’s recommendation** to ease restrictions on key neuroprotective peptides like **Epitalon and Semax**. The focus remains on **AI-driven brain health diagnostics** and **innovative cognitive treatments**.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Firefly Neuroscience, Inc.. News trend score: 44. Reason: 3 of the last 8 articles are negative, versus 2 positive.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
64
🎯 Conviction (vs. Emotion)
66
Psychology
74
Fundamentals
31
Technical
70
Valuation
50
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
-8%
Market Narrative
62
Fundamental Reality
66
Narrative Gap
-4
🔀 Weak-Conviction Rally
Price is moving, but not accompanied by a matching rise in news attention/sentiment.
🧠 StockIQ Psychologist
The dominant **Loss Aversion** (68) reflects a market wary of deeper declines after a 28.5% drop, despite modest momentum. Overconfidence (12) suggests some investors bet on price outperforming fundamentals, but FOMO (16) remains muted due to neutral RSI and sentiment. The **narrative gap** (-19) hints at a disconnect where reality (price action) may not fully justify current sentiment. The key question: Will volume sustain or will the 3-month decline trigger further defensive positioning?
Updated: 09/09/2026, 01:07 AM
What could change this?
👥 What the crowd believes
"FDA Advisory Committee’s recommendation backs broader access to key neuroprotective peptides"
"Firefly Neuroscience and Next Health Partner To Launch Precision Cognitive Health Platform"
🧠 Market Brain events driving this
📈 4D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 77/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
The stark divide in verdicts for AIFF reflects deep methodological differences in how these investors evaluate risk, timing, and valuation. Charles Mackay’s high score suggests the stock lacks crowd-driven mania, while Howard Marks’ mid-range scores see it as early-to-mid cycle, not yet overextended—both implying a measured, cautious approach. In contrast, Fisher, Graham, and Lynch’s low scores reject it outright, either for lacking growth potential, failing valuation tests, or not meeting their core criteria for long-term holdings. Meanwhile, Veblen and Housel’s near-zero scores flag it as speculative or volatile, aligning with their focus on behavioral risks and patience. The spread from Mackay’s 91 to Housel’s 0 underscores that some frameworks prioritize relative calm (avoiding bubbles) while others demand strict fundamentals or trend alignment—leaving little consensus beyond a few investors seeing *some* room for cautious consideration.
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 77
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 69
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 66
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 50
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 50
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 45
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 45
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 41
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 39
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 39
Liquidity position Bagehot would flag as a real risk
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 35
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 28
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 24
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 20
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 12
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 283 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (8 bullish · 2 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
56.5%
Operating Margin
-775.5%
Net Margin
-1741.0%
EBITDA Margin
-760.4%
ROE
-260.3%
ROA
-189.8%
ROIC
—
EPS
-$1.97
Cash
—
Total Debt
—
Current Ratio
1.43
Debt/Equity
—
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$0.61
Tangible Book Value per Share (Tangible NAV)
$0.13
Sentiment based on basic keywords (not AI) — 2 positive, 3 neutral, 3 negative out of the last 8 articles.
Benzinga · 18.9.2026
Benzinga · 18.9.2026
Yahoo · 17.9.2026
Benzinga · 17.9.2026
Benzinga · 14.9.2026
GlobeNewswire · 5.8.2026
GlobeNewswire · 28.7.2026
Benzinga · 28.7.2026
Firefly Neuroscience, Inc. (AIFF) currently has a StockIQ AI score of 48/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
AIFF currently scores 48/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
AIFF's technical score is 70/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 957.4%; Price is above the 50-day average; MACD histogram is positive — rising momentum.
Based on the real signals StockIQ computed: Operating margin: -775.5% (negative); Net margin: -1741.0% (negative); Operating margin is eroding over time.
StockIQ has no recorded dividend payment history for AIFF.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 15 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Lipschitz Gregory | Grant/Award from Employer | 10.3.2026 | 530,184 | +65,988 | — |
| DeCaprio David | Grant/Award from Employer | 10.3.2026 | 77,866 | +44,872 | — |
| DeCaprio David | Grant/Award from Employer | 10.3.2026 | 44,872 | +44,872 | — |
| Lipschitz Gregory | Grant/Award from Employer | 10.3.2026 | 65,988 | +65,988 | — |
| POSNER BRIAN M | Grant/Award from Employer | 28.10.2025 | 65,929 | +49,262 | — |
| Menawat Arun Swarup | Grant/Award from Employer | 28.10.2025 | 90,559 | +73,892 | — |
| Vnook Stella | Grant/Award from Employer | 28.10.2025 | 65,929 | +49,262 | — |
| POSNER BRIAN M | Grant/Award from Employer | 28.10.2025 | 49,262 | +49,262 | — |
| Vnook Stella | Grant/Award from Employer | 28.10.2025 | 49,262 | +49,262 | — |
| Menawat Arun Swarup | Grant/Award from Employer | 28.10.2025 | 73,892 | +73,892 | — |
| HJRK Holdings Inc. | Open Market Sale | 22.10.2025 | 1,236,773 | -78,031 | $2.07 |
| Windsor Private Capital LP | Open Market Sale | 22.10.2025 | 78,031 | -78,031 | $2.07 |
| HJRK Holdings Inc. | Open Market Sale | 21.10.2025 | 1,314,804 | -19,222 | $2.40 |
| Windsor Private Capital LP | Open Market Sale | 21.10.2025 | 19,222 | -19,222 | $2.40 |
| HJRK Holdings Inc. | Open Market Sale | 20.10.2025 | 1,334,026 | -33,500 | $2.46 |
| Windsor Private Capital LP | Open Market Sale | 20.10.2025 | 33,500 | -33,500 | $2.46 |
| HJRK Holdings Inc. | Open Market Sale | 17.10.2025 | 1,367,526 | -45,036 | $2.55 |
| Windsor Private Capital LP | Open Market Sale | 17.10.2025 | 45,036 | -45,036 | $2.55 |
| HJRK Holdings Inc. | Open Market Sale | 16.10.2025 | 1,412,562 | -40,139 | $2.65 |
| Windsor Private Capital LP | Open Market Sale | 16.10.2025 | 40,139 | -40,139 | $2.65 |
| HJRK Holdings Inc. | Open Market Sale | 15.10.2025 | 1,452,701 | -17,500 | $2.74 |
| Windsor Private Capital LP | Open Market Sale | 15.10.2025 | 17,500 | -17,500 | $2.74 |
| HJRK Holdings Inc. | Open Market Sale | 14.10.2025 | 1,470,201 | -29,500 | $2.74 |
| Windsor Private Capital LP | Open Market Sale | 14.10.2025 | 29,500 | -29,500 | $2.74 |
| HJRK Holdings Inc. | Open Market Sale | 13.10.2025 | 1,499,701 | -32,136 | $2.65 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
422,220 shares short as of 2026-08-31 · vs. 598,458 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
50.2% of trading volume this week was short selling, vs. 31.9% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology